Asunto(s)
Terapia de Inmunosupresión , Neoplasias/inmunología , Antígenos CD/inmunología , Antígenos de Diferenciación/inmunología , Apoptosis , Enfermedades Autoinmunes/terapia , Citocinas/inmunología , Células Dendríticas/inmunología , Humanos , Interleucinas/inmunología , Células Asesinas Naturales/inmunología , Activación de Linfocitos , Complejo Mayor de Histocompatibilidad/inmunología , Neoplasias/terapia , Factores de Riesgo , Linfocitos T/inmunologíaAsunto(s)
Neoplasias de la Mama/terapia , Factor Estimulante de Colonias de Granulocitos y Macrófagos/uso terapéutico , Trasplante de Células Madre Hematopoyéticas/métodos , Interferones/uso terapéutico , Interleucina-2/uso terapéutico , Leucemia Mielógena Crónica BCR-ABL Positiva/terapia , Femenino , Humanos , MasculinoAsunto(s)
Linfoma Relacionado con SIDA , Corticoesteroides/uso terapéutico , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias Encefálicas/tratamiento farmacológico , Neoplasias Encefálicas/epidemiología , Neoplasias Encefálicas/microbiología , Neoplasias Encefálicas/patología , Neoplasias Encefálicas/radioterapia , Terapia Combinada , Irradiación Craneana , Predicción , Humanos , Incidencia , Linfoma Relacionado con SIDA/tratamiento farmacológico , Linfoma Relacionado con SIDA/epidemiología , Linfoma Relacionado con SIDA/patología , Linfoma Relacionado con SIDA/radioterapia , Persona de Mediana Edad , PronósticoAsunto(s)
Factores de Crecimiento de Célula Hematopoyética/uso terapéutico , Síndrome de Inmunodeficiencia Adquirida/tratamiento farmacológico , Trasplante de Médula Ósea/efectos adversos , Factores Estimulantes de Colonias/uso terapéutico , Eritropoyetina/metabolismo , Eritropoyetina/uso terapéutico , Humanos , Neoplasias/tratamiento farmacológico , Neoplasias/radioterapia , Neutropenia/inducido químicamente , Neutropenia/etiología , Neutropenia/terapia , Factor de Necrosis Tumoral alfa/metabolismo , Zidovudina/efectos adversosRESUMEN
Heterosexual couples of individuals infected by HIV represent a group of high risk of virus infection. We have investigated the presence of fragments of the HIV genome with a new nucleic acid amplification technique (PCR or polymerase chain reaction) in lymphocytes from 33 seronegative couples with anti-HIV antibodies, most of which were heroin addicts. 12 of the 33 couples (36%) had positive PCR for a gag HIV amplimer in the absence of antibodies. 4 of them (12%) also showed reactivity for sequences from an env amplimer. A control group of 7 patients with AIDS and 4 seropositive couples showed reactivity to gag and env in all. It is concluded that silent HIV infection may frequently develop in heterosexual couples of infected individuals.
Asunto(s)
Síndrome de Inmunodeficiencia Adquirida/transmisión , ADN Viral/genética , Genes Virales/genética , VIH-1/genética , Técnicas de Amplificación de Ácido Nucleico , Conducta Sexual , Serodiagnóstico del SIDA , Síndrome de Inmunodeficiencia Adquirida/diagnóstico , Síndrome de Inmunodeficiencia Adquirida/genética , Femenino , Amplificación de Genes/genética , Seropositividad para VIH/diagnóstico , Seropositividad para VIH/genética , Seropositividad para VIH/transmisión , Humanos , MasculinoAsunto(s)
Infecciones por HTLV-I/etiología , Reacción a la Transfusión , Anciano , Femenino , Humanos , Masculino , EspañaRESUMEN
The presence of antibodies against HTLV-I was investigated with ELISA and Western blot techniques in 76 patients with lymphoproliferative syndromes (n = 53), idiopathic subacute myelopathies (n = 4), chronic T-lymphocytosis (n = 3) and collagen vascular diseases (n = 16) diagnosed in the Barcelona area. 9 HIV seropositive patients were included: 7 with lymphoma, 1 with chronic T-lymphocytosis and 1 with polymyositis. Although 3 samples were repeatedly positive with ELISA, none was confirmed with Western blot. These results suggest that in our country, contrasting with areas where HTLV-I infection is endemic, acute and chronic lymphoproliferative diseases, collagen vascular diseases and demyelinating neurologic diseases are not associated with HTLV-I infection. The development of lymphoma in patients seropositive for HIV also could not be related with HTLV-I infection.
Asunto(s)
Enfermedades del Colágeno/sangre , Enfermedades Desmielinizantes/sangre , Anticuerpos Anti-HTLV-I/sangre , Trastornos Linfoproliferativos/sangre , Paraparesia Espástica Tropical/sangre , Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , EspañaRESUMEN
We report 7 individuals in whom HIV seroconversion developed, in 6 associated with symptoms and in one without any symptom at all. The most florid and sustained symptoms appeared in the oldest patients: a female and her heterosexual partner, who was a promiscuous male with recent seroconversion. A heroin abuser had oral muguet, and another had esophageal candidiasis. Rash was absent in all cases. Antigenemia was demonstrated in 6 of the 7 patients. In one case, a third generation ELISA was more sensitive than Western blot for the identification of seroconversion.
Asunto(s)
Seropositividad para VIH/inmunología , Adulto , Salud de la Familia , Femenino , Seropositividad para VIH/sangre , Seropositividad para VIH/complicaciones , Seropositividad para VIH/transmisión , Humanos , Masculino , Factores de RiesgoRESUMEN
Blood pressure and clinical status of 1,736 patients with cerebrovascular disease were observed during 12 months of treatment with nicardipine. The most common diagnoses were chronic cerebral ischemia (53.2%), transient ischemic attacks (TIA; 25.1%), and cerebral infarct (8.7%); 50.1% of patients were classed as hypertensive [systolic blood pressure (SBP) > or = 160 mm Hg or diastolic blood pressure (DBP) > or = 90 mm Hg]. Most patients (91.2%) received a daily dose of 60 mg nicardipine. Additional treatments included diuretics (37%), beta-blockers (11.5%), other antihypertensive drugs (15.8%), platelet antiaggregants (25.1%), and cardiotonic drugs (15.1%). A total of 282 patients (16.2%) were lost to follow-up, 21 (1.2%) patients withdrew due to side effects, 32 (1.8%) died, and 9 (0.5%) patients had treatment interrupted due to concomitant illness. In the hypertensive subgroup, blood pressure (SBP/DBP) was reduced from a mean baseline value of 175 +/- 22/97 +/- 14 mm Hg to 152 +/- 17/85 +/- 11 mm Hg at 3 months and 149 +/- 23/81 +/- 11 mm Hg after 12 months of treatment. The incidence of TIA or stroke among these patients was reduced from 29 cases (3.5%) during the first 3 months to 11 cases (1.54%) during months 4-12 (p < 0.01). In normotensive patients there were 18 (2.15%) cases during months 1-3 and 13 (1.55%) cases during months 4-12 (difference not significant). In the 280 patients treated with nicardipine alone, the most frequent side effects during the first month were facial flushing (6.8%), gastrointestinal problems (5%), dizziness (3.2%), headache (3.2%), drowsiness (3.2%), and hypotension (1.1%). Most of these side effects were transient.(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Trastornos Cerebrovasculares/prevención & control , Nicardipino/uso terapéutico , Anciano , Anciano de 80 o más Años , Trastornos Cerebrovasculares/etiología , Susceptibilidad a Enfermedades , Femenino , Humanos , Masculino , Persona de Mediana Edad , Factores de RiesgoRESUMEN
The antiemetic effect of a new benzamide, alizapride, was investigated with escalating doses through four levels starting at 5 mg/kg/cycle up to 20 mg/kg/cycle. 39 patients were accrued who received cancer chemotherapy which included the following drugs in various combinations: cyclophosphamide, adriamycin, fluorouracil, carboplatin and etoposide (VP-16). Complete control of emesis was achieved in a third of the 39 patients. There was no statistically significant difference among the dose levels with regard to the patient's assessment of the incidence and severity of nausea and vomiting. Alizapride was well tolerated at all dose levels tested with minimal toxicity. Mild sedation was reported in 60% of the patients. Neither extrapyramidal reactions nor hypotensive side effects were observed. Thus the therapeutic yield of alizapride could be further studied concerning the optimal dose and schedule as well as its use in combination with other antiemetic drugs.
Asunto(s)
Antieméticos/uso terapéutico , Pirrolidinas/uso terapéutico , Vómitos/tratamiento farmacológico , Adulto , Anciano , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Masculino , Persona de Mediana Edad , Pirrolidinas/efectos adversos , Vómitos/inducido químicamenteAsunto(s)
Síndrome de Inmunodeficiencia Adquirida/diagnóstico , Anticuerpos Anti-VIH/análisis , Antígenos VIH/análisis , Dependencia de Heroína/complicaciones , Síndrome de Inmunodeficiencia Adquirida/complicaciones , Adolescente , Adulto , Candidiasis/diagnóstico , Enfermedades del Esófago/diagnóstico , Femenino , Humanos , MasculinoAsunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carcinoma de Células Pequeñas/tratamiento farmacológico , Neoplasias Pulmonares/tratamiento farmacológico , Adulto , Anciano , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Carcinoma de Células Pequeñas/mortalidad , Ciclofosfamida/efectos adversos , Ciclofosfamida/uso terapéutico , Doxorrubicina/efectos adversos , Doxorrubicina/uso terapéutico , Estudios de Seguimiento , Humanos , Neoplasias Pulmonares/mortalidad , Masculino , Persona de Mediana Edad , Podofilotoxina/efectos adversos , Podofilotoxina/uso terapéutico , Factores de Tiempo , Vincristina/efectos adversos , Vincristina/uso terapéuticoRESUMEN
Thirty-one patients with non-small-cell lung cancer (NSCLC), stage III (T3 N2 M 0-1), were treated with cyclophosphamide (400 mg/m2), adriamycin (40 mg/m2) and cisplatin (60 mg/m2) (CAP) every 4 weeks for 8 cycles. Twenty-six patients were evaluable for response. Patients characteristics included: median age, 63 years; median performance status, 70% (range 60%-100%). One hundred and fifty-five cycles of chemotherapy were administered with a median of 5. There were 9 partial responses and 3 complete remissions, for an overall response rate of 46%. The median survival duration was 9 months, and 29% survived 1 year. CAP combination chemotherapy was well tolerated without nephrotoxicity, which can be imputed to the strong saline hydration given. Seventy percent of the patients did not experience emesis due to the antiemetic regimen used.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias Pulmonares/tratamiento farmacológico , Adulto , Anciano , Cisplatino/efectos adversos , Cisplatino/uso terapéutico , Ciclofosfamida/efectos adversos , Ciclofosfamida/uso terapéutico , Doxorrubicina/efectos adversos , Doxorrubicina/uso terapéutico , Humanos , Neoplasias Pulmonares/mortalidad , Masculino , Persona de Mediana EdadRESUMEN
Forty-four previously untreated patients with advanced non-small-cell lung cancer were treated in a randomized trial comparing platinum (60 mg/m2), doxorubicin (40 mg/m2), and VP-16 (150 mg/m2) (PAV) with platinum (60 mg/m2), 4'-epidoxorubicin (50 mg/m2), and VP-16 (150 mg/m2) (PEV). The overall response rate was 10%. Major response rates were quite similar for the 21 patients treated with PAV (5%) and the 23 patients treated with PEV (18%) (p = 0.2). Of the 23 patients with assigned to PEV, two (9%) achieved complete responses for a median duration of 20 weeks and 44+ weeks. There was no significant difference (p = 0.75) in the median survival among patients treated with PAV (24 weeks) and those treated with PEV (20 weeks). Toxicity was generally mild and tolerable. The lack of response found in both arms of treatment caused the study to be terminated early. Some benefit could be appreciated in patients with limited disease and good Karnofsky performance status.